Evidence map›Paper›PMID 30778911›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2019

Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration.

Joanna Porażka, Edyta Szałek, Wojciech Połom, Mateusz Czajkowski, Tomasz Grabowski, Marcin Matuszewski, Edmund Grześkowiak

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05081765 (The Effect of Glucose Level and Diabetes Mellitus on the Plasma Minimum Steady-state Concentration Ctrough of Olaparib in Patients With Ovarian Cancer), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05081765 unknown statusnot on this mapstarted 2021, after this paper: background citation

The Effect of Glucose Level and Diabetes Mellitus on the Plasma Minimum Steady-state Concentration Ctrough of Olaparib in Patients With Ovarian Cancer

Typeobservational_patient_registrySponsorPoznan University of Medical SciencesRan2021 to 2022Enrolled40ConditionsOvary CancerArmsLynparza® (AstraZeneca Pharma Poland Sp. z o.o.), Lynparza
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Joanna PorażkaDepartment of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, ul. Św. Marii Magdaleny 14, 61-861, Poznań, Poland. joanna.porazka@gmail.com.ORCID http://orcid.org/0000-0003-0171-7532
Edyta SzałekDepartment of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, ul. Św. Marii Magdaleny 14, 61-861, Poznań, Poland.
Wojciech PołomDepartment of Urology, Medical University of Gdansk, ul. Smoluchowskiego 17, 80-214, Gdańsk, Poland.
Mateusz CzajkowskiDepartment of Urology, Medical University of Gdansk, ul. Smoluchowskiego 17, 80-214, Gdańsk, Poland.
Tomasz GrabowskiPolpharma Biologics, ul. Trzy lipy 3, 80-172, Gdańsk, Poland.
Marcin MatuszewskiDepartment of Urology, Medical University of Gdansk, ul. Smoluchowskiego 17, 80-214, Gdańsk, Poland.
Edmund GrześkowiakDepartment of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, ul. Św. Marii Magdaleny 14, 61-861, Poznań, Poland.
Gdańsk Medical University · PLPoznan University of Medical Sciences · PLSciencePharma (Poland) · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe number of overweight, obese and diabetic patients is constantly increasing. Metabolic disorders may affect the pharmacokinetics of drugs, e.g., by altering the activity of cytochrome P450 (CYP) isoenzymes. Tramadol is a commonly used analgesic metabolised mainly via CYP2D6 to its active metabolite, O-desmethyltramadol. The aim of the study was to assess the influence of overweight, obesity and type 2 diabetes mellitus on tramadol and O-desmethyltramadol pharmacokinetics.

methodsAll patients received a single oral dose (100 mg) of tramadol. The plasma concentrations of tramadol and O-desmethyltramadol were measured with the validated high-performance liquid chromatography method with fluorescence detection. The pharmacokinetic parameters of tramadol and O-desmethyltramadol were calculated by non-compartmental methods.

resultsAfter nephrectomy, the patients were divided into four groups-a control group (n = 12, mean [SD] age 61 [14] years, body mass index (BMI) 22 [2] kg/m

conclusionsNo significant differences were found in the pharmacokinetics of tramadol and O-desmethyltramadol, indicating that the opioid can be administered to overweight, obese and diabetic patients without dosage adjustment.

Indexed as

Administration, OralAdultAgedAged, 80 and overAnalgesics, OpioidChromatography, High Pressure LiquidCytochrome P-450 Enzyme SystemDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedObesityTramadolAnalgesics, OpioidCytochrome P-450 Enzyme SystemO-demethyltramadolTramadol

Identifiers

PMID30778911
PMCPMC6616205
OpenAlexW2915730910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.